Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Summary
Randomized, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.
Official title: Randomized, Placebo-controlled Phase 3 Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
984
Start Date
2026-05
Completion Date
2030-11
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
HPV vaccine
HPV vaccine, 3 timepoints : month 0, month 1-2, month 6
Placebo vaccine
Placebo vaccine, 3 timepoints : month 0, month 1-2, month 6